|
Cost-effectiveness Assessment of Telaprevir Combination Treatment Compared to Pegylated-Interferon + Ribavirin Alone
in the Management of Chronic Hepatitis C in Patients Who Failed a Prior Pegylated-Interferon + Ribavirin Treatment
|
|
|
Reported by Jules Levin
Presented at the 62nd Annual Meeting for the American Association for the Study of Liver Diseases, San Francisco, CA, USA, November 4-8 2011
Baris Deniz, MSc1; Anita J Brogan, PhD2; Jeffrey D Miller, MS3; Sandra E Talbird, MSPH2; James R Thompson, MS2
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 2RTI Health Solutions, Research Triangle Park, NC, United States; 3RTI Health Solutions, Waltham, MA, United States
![AASLD1.gif](../images/112111/112111-4/AASLD1.gif)
![AASLD2.gif](../images/112111/112111-4/AASLD2.gif)
![AASLD3.gif](../images/112111/112111-4/AASLD3.gif)
![AASLD4.gif](../images/112111/112111-4/AASLD4.gif)
![AASLD5.gif](../images/112111/112111-4/AASLD5.gif)
![AASLD6.gif](../images/112111/112111-4/AASLD6.gif)
![AASLD7.gif](../images/112111/112111-4/AASLD7.gif)
![AASLD8.gif](../images/112111/112111-4/AASLD8.gif)
![AASLD9.gif](../images/112111/112111-4/AASLD9.gif)
![AASLD10.gif](../images/112111/112111-4/AASLD10.gif)
![AASLD11.gif](../images/112111/112111-4/AASLD11.gif)
|
|
|
|
|
|
|